- Home
- KRON vs DYAI Comparison
KRON vs DYAI Comparison
Compare KRON & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- DYAI
- Stock Information
- Founded
- KRON 2017
- DYAI 1979
- Country
- KRON United States
- DYAI United States
- Employees
- KRON N/A
- DYAI N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRON Health Care
- DYAI Health Care
- Exchange
- KRON Nasdaq
- DYAI Nasdaq
- Market Cap
- KRON 59.1M
- DYAI 54.4M
- IPO Year
- KRON 2020
- DYAI 2004
- Fundamental
- Price
- KRON $0.99
- DYAI $1.50
- Analyst Decision
- KRON Buy
- DYAI Strong Buy
- Analyst Count
- KRON 3
- DYAI 1
- Target Price
- KRON $1.63
- DYAI $6.00
- AVG Volume (30 Days)
- KRON 292.4K
- DYAI 213.3K
- Earning Date
- KRON 11-13-2024
- DYAI 11-12-2024
- Dividend Yield
- KRON N/A
- DYAI N/A
- EPS Growth
- KRON N/A
- DYAI N/A
- EPS
- KRON N/A
- DYAI N/A
- Revenue
- KRON $9,864,000.00
- DYAI $3,364,548.00
- Revenue This Year
- KRON $62.21
- DYAI $51.30
- Revenue Next Year
- KRON N/A
- DYAI $73.26
- P/E Ratio
- KRON N/A
- DYAI N/A
- Revenue Growth
- KRON 146.48
- DYAI 13.82
- 52 Week Low
- KRON $0.69
- DYAI $0.93
- 52 Week High
- KRON $1.60
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- KRON 53.69
- DYAI 42.12
- Support Level
- KRON $0.92
- DYAI $1.45
- Resistance Level
- KRON $1.02
- DYAI $1.79
- Average True Range (ATR)
- KRON 0.05
- DYAI 0.24
- MACD
- KRON 0.00
- DYAI -0.05
- Stochastic Oscillator
- KRON 77.38
- DYAI 7.25
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.